| Schedule of Revenue Recognized in Unaudited Condensed Consolidated Interim Statements of Profit or Loss |
Revenue has been recognized in the unaudited condensed consolidated interim statements of profit or loss with the following amounts:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
September 30, |
|
|
Nine Months Ended
September 30, |
|
(EUR’000) |
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
Revenue |
|
|
|
|
|
|
|
|
|
|
|
|
Commercial products |
|
|
193,790 |
|
|
|
55,710 |
|
|
|
443,480 |
|
|
|
153,598 |
|
Rendering of services and clinical supply |
|
|
6,134 |
|
|
|
1,272 |
|
|
|
13,228 |
|
|
|
9,637 |
|
Licenses |
|
|
788 |
|
|
|
851 |
|
|
|
3,002 |
|
|
|
26,490 |
|
Milestones |
|
|
12,922 |
|
|
|
— |
|
|
|
12,922 |
|
|
|
— |
|
Total revenue |
|
|
213,634 |
|
|
|
57,833 |
|
|
|
472,632 |
|
|
|
189,725 |
|
Specified per geographical area |
|
|
|
|
|
|
|
|
|
|
|
|
Europe (1) |
|
|
33,381 |
|
|
|
8,151 |
|
|
|
82,602 |
|
|
|
14,800 |
|
North America |
|
|
161,133 |
|
|
|
48,758 |
|
|
|
343,266 |
|
|
|
170,833 |
|
Rest of world |
|
|
19,120 |
|
|
|
924 |
|
|
|
46,764 |
|
|
|
4,092 |
|
Total revenue |
|
|
213,634 |
|
|
|
57,833 |
|
|
|
472,632 |
|
|
|
189,725 |
|
For the three and nine months ended September 30, 2025, Denmark, the country of domicile, contributed with €4.1 million and €9.1 million, respectively, of revenue. For the three and nine months ended September 30, 2024, no revenue was attributable to Denmark.
|
| Schedule of Revenue From Sale of Commercial Products |
Revenue from sale of commercial products were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
September 30, |
|
|
Nine Months Ended
September 30, |
|
(EUR’000) |
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
Revenue from commercial products |
|
|
|
|
|
|
|
|
|
|
|
|
SKYTROFA® |
|
|
50,701 |
|
|
|
47,249 |
|
|
|
152,745 |
|
|
|
138,455 |
|
YORVIPATH® |
|
|
143,089 |
|
|
|
8,461 |
|
|
|
290,735 |
|
|
|
15,143 |
|
Total revenue from commercial products |
|
|
193,790 |
|
|
|
55,710 |
|
|
|
443,480 |
|
|
|
153,598 |
|
|